
Tirzepatide Advancements, GLP-1 Controversies, and Nasal Spray Epinephrine Breakthroughs
In today's episode, Dr. Chi-Ming Chow delves into the latest advancements in diabetes and weight loss treatments, starting with Eli Lilly's tirzepatide. He explains the drug's mechanism, effects, and considerations for long-term use. The episode also addresses emerging concerns regarding semaglutide and its potential mental health risks. Dr. Chow discusses the controversies and provides recommendations for GLP-1 drug prescriptions. Additionally, he explores the link between meat consumption and type 2 diabetes risk. The episode concludes with a breakthrough in allergy treatment: nasal spray epinephrine, highlighting its advantages and considerations.
G
You're chatting with AI hosts from Morning Medical with Dr. Chow.
- / -